DexComDXCM
DXCM
About: Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
Employees: 9,600
0
Funds holding %
of 6,823 funds
0
Analysts bullish %
of 10 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
5% less call options, than puts
Call options by funds: $405M | Put options by funds: $424M
6% less repeat investments, than reductions
Existing positions increased: 325 | Existing positions reduced: 344
7.55% less ownership
Funds ownership: 96.97% [Q2] → 89.41% (-7.55%) [Q3]
12% less funds holding
Funds holding: 982 [Q2] → 868 (-114) [Q3]
36% less funds holding in top 10
Funds holding in top 10: 14 [Q2] → 9 (-5) [Q3]
45% less capital invested
Capital invested by funds: $43.7B [Q2] → $24B (-$19.7B) [Q3]
51% less first-time investments, than exits
New positions opened: 98 | Existing positions closed: 199
Research analyst outlook
10 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$85
1%
upside
Avg. target
$97
14%
upside
High target
$115
36%
upside
10 analyst ratings
9 positive
90%
1 neutral
10%
0 negative
0%
Baird Jeff Johnson 36% 1-year accuracy 5 / 14 met price target | 23%upside $104 | Outperform Upgraded | 16 Jan 2025 |
Citigroup Joanne Wuensch 60% 1-year accuracy 28 / 47 met price target | 8%upside $91 | Buy Maintained | 11 Dec 2024 |
Wells Fargo Larry Biegelsen 63% 1-year accuracy 29 / 46 met price target | 11%upside $94 | Overweight Maintained | 11 Dec 2024 |
Canaccord Genuity William Plovanic 72% 1-year accuracy 34 / 47 met price target | 17%upside $99 | Buy Maintained | 9 Dec 2024 |
Bernstein Lee Hambright 83% 1-year accuracy 5 / 6 met price target | 2%upside $86 | Outperform Maintained | 25 Oct 2024 |
Financial journalist opinion
Based on 14 articles about DXCM published over the past 30 days
Positive
Seeking Alpha
3 days ago
DexCom: Fairly Priced In 2025; Why I'm Not Expecting A Share Price Comeback
DexCom, Inc.'s growth is impressive but limited by its niche market, with my projected ceiling being ~$7.5bn in peak annual revenues. Despite positive Q4 2024 results, DexCom's stock is fairly valued, with muted enthusiasm from Wall Street today, and a "Hold" rating for me for 2025. I suspect the market overestimated DexCom's mass-market potential, leading to a reality check and a savage bear run on its stock in the past year.
Positive
The Motley Fool
4 days ago
2 Healthcare Stocks to Buy Hand Over Fist in January
Stocks tend to perform well in January, but that's not a good reason to invest this month. Strong returns aren't made in a single 30-day period.
Positive
CNBC
6 days ago
Healthy Returns: From Eli Lilly to Amazon, here are the latest health-care deals
Companies from Johnson & Johnson to Eli Lilly, Amazon and Nvidia are announcing health-related deals at the JPMorgan Health Care Conference.
Positive
Zacks Investment Research
6 days ago
DexCom Stock Up Following Strong Preliminary Q4 Results & 2025 Outlook
DXCM's top line reflects strong demand for its CGM sensors. International expansion is also driving sales higher.
Positive
Zacks Investment Research
1 week ago
Here's Why You Should Retain DexCom Stock in Your Portfolio for Now
DXCM continues to raise optimism among investors owing to its strong product portfolio.
Neutral
Reuters
1 week ago
Dexcom forecasts 2025 revenue mostly in-line with expectations
Dexcom forecast total annual revenue in line with Wall Street expectations on Monday, on bets of strong demand for its continuous glucose monitors for diabetes patients.
Neutral
Business Wire
1 week ago
Dexcom Reports Preliminary, Unaudited Results for the Fourth Quarter and Fiscal Year 2024 and Initial 2025 Outlook
SAN DIEGO--(BUSINESS WIRE)--Dexcom Reports Preliminary, Unaudited Results for the Fourth Quarter and Fiscal Year 2024 and Initial 2025 Outlook.
Neutral
The Motley Fool
1 week ago
3 Beaten-Down Stocks That May Be Due for Big Comebacks in 2025
The past year was a great one for the stock market as a whole, but there were plenty of companies that didn't do well in 2024. Shares of Celsius Holdings (CELH 0.93%), DexCom (DXCM -0.66%), and Nike (NKE 0.12%) all fell by more than 30% during the year, as investors weren't thrilled with their results.
Neutral
Business Wire
1 week ago
Dexcom to Present at 43rd Annual J.P. Morgan Healthcare Conference
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the 43rd annual J.P. Morgan Healthcare Conference on January 13, 2025. The live presentation is scheduled to begin at approximately 12:00 PM EST and will be concurrently webcast. Links to the webcast will be available on the Dexcom Investor Relations website at investors.dexcom.com and will be archived there for future reference. About DexCom, Inc. Dexcom empowers peop.
Negative
The Motley Fool
2 weeks ago
These Were the 5 Worst-Performing Stocks in the Nasdaq-100 in 2024
Now that we've shut the door on 2024, it's useful to look back at some of the best -- and, on the flip side, some of the worst -- performers of the year on the stock market. Many outliers were in the tech sector, so it's worth taking a look at the tech-heavy Nasdaq-100 index.
Charts implemented using Lightweight Charts™